Research Reports

Key takeaways

The company established a new $20.0 million delayed draw term loan facility that can be drawn in minimum $10.0 million increments until June 30, 2027.

The facility features an interest rate equal to SOFR plus 6.50% with a 3.25% floor, interest-only payments until maturity on August 5, 2029, and includes financial covenants.

The company is not required to draw on the facility in connection with the amendment, preserving near-term cash flow flexibility.

The company must pay a 1.00% upfront fee, a 0.05% per annum delayed draw ticking fee, and certain exit and prepayment fees consistent with the original agreement.

Full analysis

The First Amendment to the Term Loan Agreement provides OrthoPediatrics with additional financial flexibility through a $20 million delayed draw facility that can be accessed as needed until June 2027. This structure allows the company to manage liquidity more efficiently by drawing capital only when required, rather than taking the full amount immediately. The interest rate terms, including the SOFR-based rate with a floor and optional payment-in-kind feature, provide cost management options while the interest-only period until 2029 preserves near-term cash flow. The amendment maintains consistency with the original agreement's fee structure and covenants, suggesting this is an extension of existing financing arrangements rather than a fundamentally new structure. The company's ability to access this capital on an as-needed basis supports disciplined capital deployment while maintaining financial flexibility for potential strategic initiatives or working capital needs.

KIDS · OrthoPediatrics Corp.

Summary

Key takeaways

Full analysis